| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 Aug 2026 | 24 Aug 2026 |
| Meeting of the Board of Directors of the Company held today i.e., on Monday, 24th August, 2026, Board, inter-alia, considered the following: 1. Noting of resignation of Ms. Hasti Doshi from the position of Independent Director. 2. Approved appointment of Mr. Suraj Mahadev Gaikwad as Additional Director (Independent and Non-Executive) of the Company. 3. Recommendation of Re-appointment of Mr. Bhavesh Dhirajlal Tanna (DIN: 03353445) as a Director, liable to retire by rotation, who has offered himself for re- appointment. 4. Convening AGM for the Financial Year 2025-26. The AGM will be held on Tuesday, 22nd September, 2026 at 04:00 PM via Video Conferencing/Other Audio-Visual Means. 5. Approved Notice of 49th Annual General Meeting of the Members of the Company. 6. Appointed Mr. Shravan Gupta (ACS: 27484, CP: 9990), as the Scrutinizer. 7. Appointment of M/s Bigshare Services Pvt Ltd. as the service provider for conducting the e-voting and video conferencing for the upcoming AGM. | ||
| Board Meeting | 12 Aug 2026 | 7 Aug 2026 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June 2026 in accordance with Regulation 33 of the SEBI Listing Regulation Pursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Wednesday, 12th August, 2026, which commenced at 1:00 PM, and concluded at 01:40 PM, Board, inter-alia, approved and taken on record the following: 1. Approved Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 along with Limited Review Report issued by the Statutory Auditors of the Company. (As Per BSE Announcement Dated on: 12/08/2026) | ||
| Board Meeting | 26 May 2026 | 21 May 2026 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 inter alia to consider and approve The Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on 31st March 2026 in accordance with Regulation 33 of the SEBI Listing Regulation. | ||
| Board Meeting | 29 Jan 2026 | 16 Jan 2026 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 inter alia to consider and approve Unaudited standalone and consolidated FInancial results for quarter ended 31st December 2025 | ||
| Board Meeting | 11 Dec 2025 | 8 Dec 2025 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/12/2025 inter alia to consider and approve As per attachment Outcome of the Board Meeting (As per BSE Announcement dated on: 11.12.2025) | ||
| Board Meeting | 31 Oct 2025 | 17 Oct 2025 |
| Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated basis) for quarter and half year ended on 30th September, 2025 Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Friday, 31st October, 2025, Board, inter-alia, considered and approved Un-Audited Financial Results (Standalone & Consolidated basis) for the Quarter and Half Year ended 30th September, 2025 along with Limited Review Report The Meeting was commenced at 04: 45 PM and concluded at 5:30 PM. (As Per BSE Announcement Dated on:31.10.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
